Immunovant, Inc. (IMVT) Stock Price & Analysis

Immunovant, Inc. (IMVT) closed at USD 29.1 on Thursday, October 22, 2026, up 2.54% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 28.38; the Oct 22, 2026 session ranged USD 27.98–29.12 on volume of 1,157,191 shares. Market capitalization is $6.01B, with a 52-week range of USD 18.51–45.42 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/IMVT.md

Key facts (IMVT)

• 1 of 80 tracked superinvestors hold IMVT (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
• Analysts: Buy (mean 2.12 on a 1–5 scale) (17 analysts), mean target USD 48.88 (range 30–66).
• Total return with dividends: 1Y +55.3% vs S&P 500 +14.9%; 5Y +250.6% vs S&P 500 +80.3%.
• Next earnings: 2026-11-09, EPS estimate USD -0.72, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IMVT)

Fiscal years end Mar. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (IMVT)

P/B 8.2x · Earnings yield -8.95%

Superinvestors (SEC 13F-HR, Q2 2026) (IMVT)

1 of 80 tracked investors hold IMVT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (IMVT)

Consensus Buy (mean 2.12 on a 1–5 scale), 17 analysts; mean target USD 48.88 (low 30, high 66).

Rating changes, last 120 days:

Total return (dividends reinvested) (IMVT)

IMVT suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed May 20, 2026.

Companies that name IMVT in their SEC reports

IMVT company outlook (results filed Aug 6, 2026)

• “The Company expects to provide further updates on its potentially registrational IMVT-1402 D2T RA program and report topline data from the proof-of-concept trial of IMVT-1402 in CLE in the second half of calendar year 2026.”
• “In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG.”
• “Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in CIDP and SjD.”
• “Immunovant's expectations regarding the availability of results of clinical trials of IMVT-1402 and whether those results may be adequate to support registration; and the Company's beliefs regarding the potential sufficiency of its cash runway.”

Quoted word-for-word from the SEC 8-K results press release.

IMVT analyst estimates and revisions

IMVT options: expected move

Options price a move of about ±13.4% (±$4.00) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±8.3% on average.

30-day implied volatility 79.7% vs 39.9% realized over the last 30 trading days. Put/call ratio (volume) 0.1. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:23 UTC)

Technical Analysis (IMVT)

Nexqual's technical model rates IMVT "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.

Analyst Ratings (IMVT)

Wall Street analysts rate IMVT "Buy" based on 17 analysts, with a mean price target of USD 48.88 (range USD 30–66), per Nexqual as of October 23, 2026 at 09:23 UTC.

Earnings (IMVT)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financials & Fundamentals (IMVT)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financial Health Score (IMVT)

Nexqual rates Immunovant, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:23 UTC.

Ownership (IMVT)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Leadership (IMVT)

Immunovant, Inc. is led by Eric Venker M.D., Pharm.D., CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.

Major Backers & Investors (IMVT)

Notable institutional backers of Immunovant, Inc. include FMR, LLC, Deep Track Capital, Lp, Fidelity, according to Nexqual as of October 23, 2026 at 09:23 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

From Immunovant, Inc.'s Latest SEC 10-K Filing (filed 2026-05-20)

Key Strengths & Strategy (as disclosed to the SEC)

• Recent industry experience with anti‑FcRn therapies has informed our approach to evaluating RA.

Partnerships

• HanAll may disagree with our interpretation of the agreement or our actions thereunder, and we may be unable to reach an agreement with HanAll regarding the future of batoclimab.
• More details on the trial design are described in the figure below: License Agreement with HanAll Biopharma Co., Ltd.

Legal & Regulatory Risks (Item 1A, quoted)

• We currently have no products that are approved for commercial sale and may never be able to develop marketable products.
• We may encounter delays or difficulties in enrolling or be unable to enroll a sufficient number of patients to complete any of our clinical trials on our current timelines, or at all, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials.
• The results of our preclinical studies and clinical trials may not support our proposed claims for our product candidates, or regulatory approval on a timely basis or at all, and the results of earlier studies and trials may not be predictive of future trial results.
• The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt